1. Scrip

Forest's Saunders ropes 2nd major sale, boosts personal brand in Actavis deal

 
• By Mandy Jackson

Forest Laboratories president and CEO Brent Saunders has positioned himself as a most-wanted man in the biopharma industry with his second multibillion-dollar sale of a specialty pharmaceutical company in less than a year.

Forest Laboratories president and CEO Brent Saunders has positioned himself as a most-wanted man in the biopharma industry with his second multibillion-dollar sale of a specialty pharmaceutical company in less than a year.

Barely five months after the deal-making cowboy took over the reins from Forest's long-time CEO Howard Solomon, the company has been sold to the generic and specialty drug maker Actavis in a deal that values Forest at $25bn (scripintelligence.com, 18 February 2014)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Scrip

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Trump’s executive order more rhetoric than action; industry grapples with Trump pricing plan; Hengrui set for this year’s biggest IPO; Sanofi’s exec’s advice to biotechs; and biotech deal return on investment falls.